CA-ALKIRA
22.11.2021 10:02:09 CET | Business Wire | Press release
Alkira Inc. has appointed Exclusive Networks, a global trusted cybersecurity specialist for digital infrastructure, as a distributor for its cloud networking as-a-service platform (CNaaS).
The deal makes Alkira’s CNaaS platform Cloud Services Exchange (CSX) available through Exclusive’s global partner ecosystem spanning 40 countries across five continents. It also underlines Exclusive’s commitment to growing its cloud portfolio in a market estimated by IDC to be on track for $1.3 trillion by 20251 .
Exclusive Networks (EXN), which posted gross sales of €2.9 billion in 2020, completed a successful Initial Public Offering and listing on Euronext Paris in September this year. The company has partnerships with some of the world’s largest and most successful cybersecurity, networking and cloud infrastructure vendors, including Fortinet, Nutanix, Palo Alto Networks, Rubrik and Sentinel One. It provides cybersecurity platforms, cloud solutions and associated value-add professional services through an extensive global partner network of specialist resellers, MSPs, CSPs, telcos and systems integrators.
Alkira has appointed Paul Couturier as Senior VP International to spearhead its expansion in the EMEA and APAC regions. Couturier is an IT industry veteran who has previously held senior management roles growing international markets for Efficient Networks, TippingPoint, Cyan, LightCyber and Palo Alto Networks. In his latest role, he managed IntSights from its European debut to its acquisition by Rapid 7.
Amir Khan, Co-Founder and Chief Executive Officer of Alkira, said: “Our vision is to simplify networking in the cloud era. As the CNaaS pioneer, Alkira has eliminated the complexities and costs of building and operating networks and seamlessly integrated cloud, multi-cloud and legacy systems – no hardware, no data center, no need to ship anything. Exclusive Networks is an ideal partner for Alkira, not only because it provides us with access to their first-class global network, but because we have a shared vision of an as-a-service future.”
Andy Travers, Executive Vice President, Worldwide Sales and Marketing for Exclusive Networks, said: “Our success has been built on bringing together best in class cybersecurity, networking and automation solutions. In the cloud era, the challenge for customers is how to integrate and manage these resources in an increasingly complex environment, while controlling costs and moving the business forward. With nothing more than a few mouse clicks, Alkira’s CNaaS enables secure hybrid cloud and multi-cloud networks to be set up in hours rather than months, and puts customers, not the big cloud providers, in the driver’s seat.
“Migration of enterprise applications to the cloud is set to double in the next two years, according to Gartner2 , so it seems inevitable that networking infrastructure will follow the same trend. Just as Alkira’s founders pioneered the SD-WAN market, we now believe they are showing the way in cloud networking.”
Alkira’s CNaaS platform simplifies provisioning, connectivity and end-to-end management of networks across cloud environments, including the integration of firewalls, IPS/IDS, and load balancers, as well as enhancing the capabilities of legacy SD-WAN solutions. It enables a flexible, unified approach to secure, high-performance networking in which customers only pay for the capacity they use, and the network automatically scales to meet changing patterns of usage and demand.
About Alkira
Alkira® developed the Network Cloud which enables enterprises to build and deploy a secure global unified multi-cloud network infrastructure as-a-service that delivers network connectivity, advanced network and services, and end-to-end visibility and governance. Alkira CSX seamlessly and securely connects branches, data centers, remote users and clouds. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP of integrated solutions and a member of the Viptela founding team. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.alkira.com or follow us @AlkiraNet
(Alkira® and Alkira Cloud Services Exchange® are registered trademarks of Alkira, Inc. All other marks are the property of their respective owners.)
About Exclusive Networks
Exclusive Networks is a global trusted cybersecurity specialist for digital infrastructure helping to drive the transition to a totally trusted digital future for all people and organisations. Our distinctive approach to distribution gives partners more opportunity and more customer relevance. Our specialism is their strength – equipping them to capitalise on rapidly evolving technologies and transformative business models. The Exclusive Networks story is a global one with a services-first ideology at its core, harnessing innovation and disruption to deliver partner value. With offices in 40 countries and the ability to service customers in over 150 countries across five continents, Exclusive Networks has a unique ‘local sale, global scale’ model, combining the extreme focus and value of local independents with the scale and service delivery of a single worldwide distribution powerhouse. Learn more at www.exclusive-networks.com or follow us @EXN_Networks
1
IDC Forecasts Worldwide "Whole Cloud" Spending to Reach $1.3 Trillion by 2025
2
Market Guide to Cloud Networking Software, Gartner, May 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom